Long-acting and extended-release formulations represent one of the most important
approaches to improving the treatment and prevention of chronic HIV infection. Long-acting …

Abstract Cabotegravir/rilpivirine (CAB/RPV) was recently approved by the US Food and
Drug Administration (FDA) as the first complete parenteral antiretroviral (ART) regimen for …

Long-acting injectable anti-retroviral therapy (LAART) may overcome barriers to long-term
adherence and improve the survival of adolescents and young people living with HIV …

Background: Adherence to antiretroviral therapy (ART) is imperative for viral suppression
and reducing HIV transmission, but many people living with HIV report difficultly sustaining …

Background Long-acting injectable antiretroviral therapy (LA ART) was found to be non-
inferior to daily oral ART in Phase 3 clinical trials. LA ART may offer an important alternative …

Thanks to advances in the field over the years, HIV/AIDS has now become a manageable
chronic condition. Nevertheless, a new set of HIV-associated complications has emerged …

Long-acting antiretroviral products have the potential to transform human immunodeficiency
virus (HIV) prevention and treatment approaches in pediatric populations. Broadly …

Objective: To review the efficacy and safety of cabotegravir (CAB) with rilpivirine (RPV) in the
treatment of HIV-1 infection. Data Sources: A literature search was performed using PubMed …

Background Dolutegravir (DTG)-based regimens have been recommended by the WHO as
the preferred first-line and second-line HIV treatment in all populations. Evidence suggests …

Objective Review the pharmacology, pharmacokinetics, efficacy, safety, and role of long-
acting injectable cabotegravir (CAB-LA) in HIV preexposure prophylaxis (PrEP). Data …